Trials / Recruiting
RecruitingNCT06658730
Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,500 (estimated)
- Sponsor
- W.L.Gore & Associates · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An observational, prospective multi-regional post-market registry collecting mid- and long-term data to assess outcomes through ten years of follow-up for subjects treated with GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System as a part of routine clinical practice. This post-market registry for the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System (CTAG w/AC) is intended to demonstrate that thoracic endovascular aortic repair (TEVAR) for lesions of the descending thoracic aorta continues to be a suitable treatment option for appropriately selected patients.
Conditions
- Vascular Disease
- Dissection
- Dissection Aortic Aneurysm
- Dissection of Aorta
- Aneurysm Thoracic
- Aneurysm Dissecting
- Transection Aorta
- Intramural Hematoma
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Endovascular | TEVAR - thoracic endovascular aortic repair |
Timeline
- Start date
- 2025-06-19
- Primary completion
- 2038-08-01
- Completion
- 2038-08-01
- First posted
- 2024-10-26
- Last updated
- 2026-01-21
Locations
10 sites across 7 countries: United States, Denmark, France, Germany, Greece, Spain, Sweden
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT06658730. Inclusion in this directory is not an endorsement.